This review paper discusses the main molecular alterations of endometrial carcinoma, the
most common cancer of the female genital tract. Two clinicopathological variants are …

In molecular cancer therapeutics only 10% of known cancer gene products are targetable
with current pharmacological agents. Major oncogenic drivers, such as MYC and KRAS …

Immune responses against thyroid carcinomas have long been demonstrated and
associations between inflammatory microenvironment and thyroid carcinomas repeatedly …

Background About 20% of patients diagnosed with endometrial cancer (EC) are considered
high-risk with unfavorable prognosis. In the framework of the European Network for …

The high efficacy of therapeutic cancer vaccines in preclinical studies has yet to be fully
achieved in clinical trials. Tumor immune suppression is a critical factor that hampers the …

The marine environment represents an outstanding source of antitumoral compounds and,
at the same time, remains highly unexplored. Organisms living in the sea synthesize a wide …

Introduction The use of nanoparticles for breast cancer targeting and treatment has become
a reality. They are safe and possess interesting peculiarities such as the unspecific …

Ion-gel systems possess many favorable features to apply for the encapsulation, protection,
and release of bioactive agents in the pharmaceutical science. The ion-gels can reinforce …

Clear cell ovarian carcinoma (CCOC) is an aggressive form of epithelial ovarian cancer that
exhibits low response rates to systemic therapy and poor patient outcomes. Multiple studies …

Relatively little is known about the antiproliferative effects of artemisinin, a naturally
occurring antimalarial compound from Artemisia annua, or sweet wormwood, in human …